{"id":408425,"date":"2021-01-05T08:03:41","date_gmt":"2021-01-05T13:03:41","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408425"},"modified":"2021-01-05T08:03:41","modified_gmt":"2021-01-05T13:03:41","slug":"cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/","title":{"rendered":"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122"},"content":{"rendered":"

<\/p>\n

CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122<\/b><\/p>\n

OXNARD, Calif.–(BUSINESS WIRE<\/a>)–CURE Pharmaceutical Holding Corp.<\/a> (\u201cCURE\u201d or the \u201cCompany\u201d) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue\u2122, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra\u00ae1<\/sup>) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process.\n<\/p>\n

\nCUREfilm Blue\u2122 utilizes the Company\u2019s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm\u2122, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience.\n<\/p>\n

\n“Since CURE was founded, moving our flagship technology CUREfilm\u2122 through the FDA regulatory process has been at the cornerstone of our pharmaceutical strategy. This approval of the IND filing from the FDA marks a significant milestone for our company, validating the value-proposition of our technology and proprietary dosage form,” said CURE CEO Rob Davidson. \u201cOur oral film technology makes complete sense to meet patients\u2019 sildenafil needs for treating ED. Our team has worked diligently for the past year to make several inroads on clinical efforts to achieve this important accomplishment and I am confident that we are optimally positioned to continue to trials in early 2021.\u201d\n<\/p>\n

\n\u201cThe erectile dysfunction market has evolved significantly over the last several years with the advent of telemedicine. Our patent pending CUREfilm Blue\u2122 oral soluble film of sildenafil citrate should bring a significant value proposition to patients, physicians and providers in the erectile dysfunction market,\u201d said CURE Chief Business Officer, Jonathan Berlent.\n<\/p>\n

\nThe global erectile dysfunction drug market is projected to reach approximately USD$6.6 Billion by 2025, at a CAGR of 6.0% over the five-year forecasted period with sildenafil representing a majority of the market according to a report by QYR Research.\n<\/p>\n

About CURE Pharmaceutical Holding Corp.<\/b><\/p>\n

\nCURE Pharmaceutical\u00ae<\/sup> is the pioneering developer of CUREform\u2122, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.\n<\/p>\n

\nAs a vertically integrated company, CURE\u2019s 25,000 square foot, FDA-registered, NSF\u00ae<\/sup> and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.\n<\/p>\n

1 <\/sup>Viagra\u00ae<\/sup> is a registered trademark of Pfizer Inc.\n<\/p>\n

Forward Looking Statement<\/i><\/b><\/p>\n

Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (\u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended (\u201cExchange Act\u201d), which are usually identified by the use of words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cseeks,\u201d \u201cshould,\u201d \u201cwill,\u201d and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE\u2019s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210105005370\/en\/<\/a><\/span><\/p>\n

Licensing Contact:
\n<\/span>
Jonathan Berlent
\n
Chief Business Officer
\n
CURE Pharmaceutical
\n
Jberlent@curepharma.com
\n<\/a>
516.660.9148<\/p>\n

Investment Contact:
\n<\/span>
Gary Zwetchkenbaum
\n
Plum Tree Consulting LLC
\n
gzplumtree@gmail.com
\n<\/a>
516.455.7662<\/p>\n

Media Contact:
\n<\/span>
Kathryn Brown
\n
CMW Media
\n
cure@cmwmedia.com
\n<\/a>
858.264.6600\n<\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology FDA Pharmaceutical Health<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122 OXNARD, Calif.–(BUSINESS WIRE)–CURE Pharmaceutical Holding Corp. (\u201cCURE\u201d or the \u201cCompany\u201d) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue\u2122, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra\u00ae1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. CUREfilm Blue\u2122 utilizes the Company\u2019s patented and proprietary fast-dissolving drug delivery platform, known … <\/p>\n

Continue reading “CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408425","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122 OXNARD, Calif.–(BUSINESS WIRE)–CURE Pharmaceutical Holding Corp. (\u201cCURE\u201d or the \u201cCompany\u201d) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue\u2122, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra\u00ae1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. CUREfilm Blue\u2122 utilizes the Company\u2019s patented and proprietary fast-dissolving drug delivery platform, known … Continue reading "CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122\",\"datePublished\":\"2021-01-05T13:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/\"},\"wordCount\":830,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/\",\"name\":\"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-05T13:03:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/","og_locale":"en_US","og_type":"article","og_title":"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122 - Market Newsdesk","og_description":"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122 OXNARD, Calif.–(BUSINESS WIRE)–CURE Pharmaceutical Holding Corp. (\u201cCURE\u201d or the \u201cCompany\u201d) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue\u2122, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra\u00ae1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. CUREfilm Blue\u2122 utilizes the Company\u2019s patented and proprietary fast-dissolving drug delivery platform, known … Continue reading \"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:03:41+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122","datePublished":"2021-01-05T13:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/"},"wordCount":830,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/","name":"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-05T13:03:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005370r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-receives-fda-approval-for-its-ind-application-for-erectile-dysfunction-product-curefilm-blue\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408425"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408425\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}